ivermectin oral / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...678910111213141516...129130»
  • ||||||||||  ivermectin oral / Generic mfg.
    Review, Journal:  Role of Cytochrome P450 2C9 in COVID-19 Treatment: Current Status and Future Directions. (Pubmed Central) -  May 15, 2023   
    However, a combination of CYP2C9 inducers, inhibitors or both, and plausibly different CYP isoforms could lead to treatment failure, hepatotoxicity or serious side effects including thromboembolism or bleeding, as observed in the combined use of azithromycin/warfarin...COVID-19 vaccines elicit immune responses that activate cytokine release, which in turn suppresses CYP expression that could be the source of compromised CYP2C9 drug metabolism and the subsequent drug-drug interaction. Future studies are recommended to determine CYP regulation in COVID-19, while recognising the involvement of CYP2C9 and possibly utilising CYP2C9 as a target gene to tackle the ever-mutating SARS-CoV-2.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Prevalence of Ivermectin use to prevent COVID-19 during the pandemic in Mato Grosso: cross-sectional home-based study. (Pubmed Central) -  May 10, 2023   
    Therefore, a need to integrate CDTI with health education on the importance of ivermectin uptake. There was a high prevalence of use of ivermectin as a method to prevent covid-19 by the population of Mato Grosso, indicating the need for strategies to inform the population about the risks of off-label use of drugs and to combat the advertising of drugs that are ineffective against COVID-19.
  • ||||||||||  ivermectin oral / Generic mfg.
    DISSEMINATED STRONGYLOIDES (Focussed Oral Room 2) -  May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_1800;    
    He was started on prednisolone (40mg daily) and mycophenolate mofetil (1000mg twice daily) for 1 month... Our case signifies need of awareness among clinicians of the risk of disseminated strongyloidiasis as a complication of the treatment with immunosuppressive medications even in non-endemic areas.
  • ||||||||||  ivermectin topical / Generic mfg.
    Journal:  P2X4 receptor modulates gut inflammation and favours microbial homeostasis in colitis. (Pubmed Central) -  Apr 26, 2023   
    Antivirals, corticosteroids, tocilizumab, and ivermectin had better outcomes; antivirals were associated with lower mortality risk. Our findings elaborate on an unrevealed etiopathophysiological mechanism by which microbiota dysbiosis induced by the P2X4 receptor influences the development of colitis, indicating that the P2X4 receptor represents a promising target for treating patients with CD and UC.
  • ||||||||||  ivermectin oral / Generic mfg., albendazole / Generic mfg.
    Enrollment change, Trial completion date, Trial primary completion date:  Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA) (clinicaltrials.gov) -  Apr 25, 2023   
    P3,  N=53000, Active, not recruiting, 
    Our findings elaborate on an unrevealed etiopathophysiological mechanism by which microbiota dysbiosis induced by the P2X4 receptor influences the development of colitis, indicating that the P2X4 receptor represents a promising target for treating patients with CD and UC. N=100000 --> 53000 | Trial completion date: Mar 2024 --> Jul 2024 | Trial primary completion date: Oct 2022 --> Jul 2023
  • ||||||||||  ivermectin oral / Generic mfg.
    Topical Lindane Treatment of Scabies Infestation and the Risk of Parkinson (Level 3 - Room 327) -  Apr 24, 2023 - Abstract #WCD2023WCD_1383;    
    This study demonstrated that scabies patients treated with topical lindane would not increased the risk of PD. However, the scabies treant with oral ivermectin and topical permethrin was proved by Taiwan Food and Drug Administration in 2017, the comparison of these treatments and the risk of PD is also needed further evaluation
  • ||||||||||  ivermectin oral / Generic mfg.
    New P4 trial:  Ivermectin/ Permethrin for Scabies (clinicaltrials.gov) -  Apr 19, 2023   
    P4,  N=60, Completed, 
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Association between ivermectin treatment and mortality in COVID-19: A hospital-based case-control study. (Pubmed Central) -  Apr 7, 2023   
    Among the survivors, the median length of stay was 11 days for patients who received ivermectin (IQR: 7-15) as well as for those who did not (IQR: 7-16). This study did not show any effect of ivermectin on in-patient mortality in patients with COVID-19 and there was no effect of the drug on the length of hospital stay among the survivors.